PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 12, 2026Pharmacogenomics0 citations

Dihydropyrimidine dehydrogenase (DPYD) genetic testing and treatment with 5-fluoropyrimidines in cancer patients: prevalence of variants with decreased activity and chemotherapy outcomes

View Full Paper
CRC RossoMFMichela FebbraroIVIoannis A. Voutsadakis

Key Points

  • The study aims to evaluate the prevalence of DPYD genetic variants and their association with chemotherapy toxicity in cancer patients.
  • Analyzed genetic variants of DPYD in oncology patients.
  • Assessed treatment with full doses of fluoropyrimidines.
  • Evaluated chemotherapy outcomes related to DPYD activity variants.
  • A significant portion of patients had DPYD variants with reduced activity.
  • These variants were linked to increased risk of toxicities from chemotherapy.
  • Variability in toxicity was observed even among patients with the same genotype.

Abstract

A sizable minority of oncology patients bear variants of DPYD with reduced activity and may be at increased risk of fluoropyrimidine toxicities if treated at full doses. However, variability within the same genotype exists.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Rosso et al. (2026) studied this question.

synapsesocial.com/papers/69b2580996eeacc4fcec7453https://doi.org/10.1080/14622416.2026.2641748
Ask AI
Helpful
Bookmark
Share
View Full Paper